DNLI Denali Therapeutics Inc.

21.12
+0.52  (+3%)
Previous Close 20.6
Open 20.58
Price To Book 3.9
Market Cap 2016503618
Shares 95,478,391
Volume 360,507
Short Ratio
Av. Daily Volume 463,413

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b commencement of dosing announced December 10, 2018. Data due 4Q 2019.
DNL201
Parkinson’s disease
Phase 1 data presented December 2018.
DNL747
Alzheimer’s disease
Phase 1b commencement of dosing announced January 8, 2019. Data due 4Q 2019.
DNL747
Amyotrophic Lateral Sclerosis

Latest News

  1. Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates
  2. Denali Therapeutics Reports First Quarter 2019 Financial Results
  3. Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
  4. Controversial Alzheimer's Disease theory could pinpoint new drug targets
  5. Here’s What Hedge Funds Think About Denali Therapeutics Inc. (DNLI)
  6. Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's
  7. 3 Biotech Stocks That Doubled After Hitting Bottom in 2018
  8. Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%?
  9. Harry Boxer’s 4 stocks running on earnings
  10. Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates
  11. Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
  12. New Research: Key Drivers of Growth for Walgreens Boots Alliance, Live Nation Entertainment, Denali Therapeutics, Haynes International, NV5 Global, and Johnson Outdoors — Factors of Influence, Major Initiatives and Sustained Production
  13. Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
  14. Genentech kills big drug study in early Alzheimer's patients
  15. Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
  16. Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
  17. The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
  18. Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
  19. The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings